AFM
KZIA

Anson Funds Management’s Kazia Therapeutics KZIA Stock Holding History

Anson Funds Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-204
Closed -$85K – 71
2015
Q4 		$85K Buy
+204
New +$99.6K 0.03% 87

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Anson Funds Management's KZIA Position: Q4 2020 in Review

Anson Funds Management sold out of Kazia Therapeutics (KZIA) in Q4 2020, closing a stake of 11,000 shares.

Anson Funds Management first reported a position in KZIA in Q1 2020 and held it in 3 quarters. The position peaked at $0 in Q3 2020. 13 funds tracked by Wall St. Rank hold KZIA as of Q4 2020.

  • Anson Funds Management reported no remaining Kazia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Anson Funds Management sold 11,000 Kazia Therapeutics shares in Q4 2020.
  • Anson Funds Management first reported a position in Kazia Therapeutics in Q1 2020 and held it in 3 quarters.
  • Anson Funds Management's Kazia Therapeutics position peaked at $0 in Q3 2020.
  • 13 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q4 2020.

Based on Anson Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.